DURHAM, N.C.--(BUSINESS WIRE)--Phase Bioscience, Inc., (PhaseBio) a development stage biotechnology company, announced today that Centocor Research and Development Inc. has licensed PhaseBio’s patented deltaPhaseTM process for use in its research applications. PhaseBio’s deltaPhase technology offers new solutions for the production and purification of protein-based therapeutics, including polypeptides, proteins or antibodies and provides substantial advantages over current biological production methods. The advantages seen with PhaseBio’s process include: increased yields, high throughput and elimination of chromatography steps for final product purification. “We are extremely pleased that Centocor has decided to extend their successful collaboration with PhaseBio,” stated Clay B. Thorp, Chairman of the Board, Phase Bioscience, Inc.
